João Ribas
Direktor/Vorstandsmitglied bei Asgard Therapeutics AB
Profil
João Ribas is currently a Director at Tribune Therapeutics AB, a Director at Asgard Therapeutics AB, and an Associate at Novo Seeds.
Previously, he worked as a Director-Finance at Companhia de Seguros Tranquilidade SA and as an Analyst at Merck Ventures BV.
Aktive Positionen von João Ribas
Unternehmen | Position | Beginn |
---|---|---|
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Private-Equity-Analyst | 01.08.2018 |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Direktor/Vorstandsmitglied | - |
Asgard Therapeutics AB
Asgard Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Asgard Therapeutics AB engages in biotechnological research and development activities. It is in use of cellular reprogramming in cancer immunotherapy, which forces cancer cells to present their own antigens to the immune system, triggering expansion of cancer cell-specific killer T cells and cancer elimination. The company was founded by Filipe Pereira, Cristiana Pires and Fábio Rosa in 2018 and is headquartered in Lund, Sweden. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von João Ribas
Unternehmen | Position | Ende |
---|---|---|
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Private-Equity-Analyst | 01.03.2018 |
Companhia de Seguros Tranquilidade SA
Companhia de Seguros Tranquilidade SA Investment ManagersFinance Seguradoras Unidas SA provides insurance services. Its products include vehicle, health, life, work accidents, multi-risk, civil responsibility, and other insurance. The company is headquartered in Lisbon, Portugal. | Finanzdirektor/CFO | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
Companhia de Seguros Tranquilidade SA
Companhia de Seguros Tranquilidade SA Investment ManagersFinance Seguradoras Unidas SA provides insurance services. Its products include vehicle, health, life, work accidents, multi-risk, civil responsibility, and other insurance. The company is headquartered in Lisbon, Portugal. | Finance |
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Finance |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Finance |
Asgard Therapeutics AB
Asgard Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Asgard Therapeutics AB engages in biotechnological research and development activities. It is in use of cellular reprogramming in cancer immunotherapy, which forces cancer cells to present their own antigens to the immune system, triggering expansion of cancer cell-specific killer T cells and cancer elimination. The company was founded by Filipe Pereira, Cristiana Pires and Fábio Rosa in 2018 and is headquartered in Lund, Sweden. | Commercial Services |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Commercial Services |